Clinical response and improvement in psoriasis symptoms in subjects with psoriatic arthritis following treatment with brodalumab, an anti-IL-17R antibody - 16/03/14
Philip Mease, MD, Swedish Medical Center and University of Washington, Seattle, WA, United States; Ajay Nirula, Amgen Inc, Thousand Oaks, CA, United States; Christopher Ritchlin, University of Rochester Medical Center, Rochester, NY, United States; Maria Greenwald, Desert Medical Advances, Palm Desert, CA, United States; Mark Genovese, Standford University, Palo Alto, CA, United States; Ngozi Erondu, Amgen Inc, Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF. This study was funded by Amgen Inc. Brodalumab is being co-developed by Amgen Inc. and AstraZeneca/MedImmune. |
Vol 70 - N° 5S1
P. AB165 - mai 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?